The industrial manufacture of patient-derived organoids (PDOs) marks a significant advancement in biomedical research.
Image Credit: Gorodenkoff/Shutterstock.com
Three-dimensional (3D) Patient-Derived Organoids (PDOs) offer enhanced predictive capabilities and have the potential to serve as more clinically relevant models in applications traditionally reliant on two-dimensional (2D) cell lines, including high-throughput screening (HTS), genetic engineering and co-culture assays.
Despite these advantages, the widespread adoption of PDOs is currently hindered by challenges in producing them in sufficient quantities with the necessary quality and reproducibility.
Molecular Devices now offers a solution with its 3D Ready™ Organoids and the 3D Ready Organoid Expansion Service. Its proprietary bioreactor system is designed for the controlled, large-scale production of standardized PDOs.
These organoids are cultivated in a regulated environment that ensures the continuous delivery of essential nutrients and growth factors while preventing the accumulation of toxins that can compromise cell viability.
This innovative approach facilitates the large-scale production of assay-ready organoids that are viable and consistently sized across batches. 3D Ready Organoids are provided as cryopreserved vials, ensuring convenience for plating at the discretion of the user.
Download the full app note
Acknowledgments
Produce from materials originally authored by Carly Bunston, Harman Chaggar, Kim Luetchford and Giusy Tornillo from Molecular Devices.
About Molecular Devices UK Ltd
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.